Straumann Holding Ag · SIX:STMN
Straumann — EAO Munich 2005
37 slides from Straumann's conference presentation, September 2005
Slide 1: Increasing the standard of patient care with clinically-proven technologies
Increasing the standard of patient care with clinically-proven technologies Gilbert Achermann President & CEO EAO Munich September 2005
Slide 2: Agenda
Agenda • Straumann – the innovator in implant dentistry • SLActive – the scientific evidence • New product launches • Q&A 2
Slide 3: Straumann - the innovator in implant dentistry
Straumann - the innovator in implant dentistry 1974 Straumann pioneers the one-stage surgical procedure, the rough implant surface, and an implant design that respects biologic width. 1986 Straumann introduces the morse taper connection, which is widely used in the industry today. 1997 Straumann int
Slide 4: Innovation - from topography to chemistry
Innovation - from topography to chemistry 1974 1994 2005 TPS SLA SLActive SLActive Macro Micro Molecular Development of Development surface of surface topography chemistry 4
Slide 5: Why do we need a new implant surface?
Why do we need a new implant surface? 5
Slide 6: Clinical issues in early treatment period
Clinical issues in early treatment period Today: • Most implant failures occur in the first 8 weeks* • Costs of early implant failure fall back on doctor Trend: • Increasing number of doctors placing implants • Broader criteria for patient selection • More aggressive approach to shorten treatment pl
Slide 7: A new standard of patient care
A new standard of patient care ‘We have devoted more innovation and research capacity and more resources to SLActive than to any other new product in the history of our company…’ • To reduce the risk of early implant failure • To increase safety in critical situations/indications • To provide new tr
Slide 8: What is SLActive?
Z straumann What is SLActive?
Slide 9: SLA + Active
SLA + Active SLA: Scientifically proven, state-of-the- art surface; current benchmark for healing times + Active: Chemically activated and specially conditioned for the human body 9
Slide 10: What makes SLActive so special?
What makes SLActive so special? • First chemically activated, hydrophilic implant surface • First implant surface with proven direct protein adsorption • First implant technology proven to eliminate the stability dip • First implant technology proven to cut healing times to 3-4 weeks • First active
Slide 11: Concept of SLActive (film)
Concept of SLActive (film) 11
Slide 12: SLActive - the outstanding body of scientific evidence
SLActive - the outstanding body of scientific evidence Tobias Richter Senior Marketing Manager 12
Slide 13: SLActive – naturally attractive
SLActive – naturally attractive 1. Chemical activity Enhances direct protein adsorption and blood-cell attachment 2. Hydrophilicity Provides a larger accessible surface area for increased blood contact and bone-cell attachment 13
Slide 14: Clinical issue: eliminating the dip
Clinical issue: eliminating the dip 100 Critical loading time 75 at 2-4 weeks Bone contact (%) 50 Primary stability Secondary stability (old bone) (new bone) 25 0 0 1 2 3 4 5 6 7 8 Weeks Source: S. Raghavendra, M. Wood, T.D. Taylor: Early wound healing adjacent to endosseous dental implants: a revie
Slide 15: 13 studies on SLActive
4 Z straumann 13 studies on SLActive sly ding mare STUDIES © Mom bone en suthiea ec elias) * Buser etal. * Higher Implant sta tilty (Remand tiqol * Forguson, Buser of all * Implan dablry (SLA® ys. SlActvel n fovrounck = * Cochran Pre-dinical studies * Perallal croup shy te comeere immediate va | # C
Slide 16: Key studies
Key studies Buser et al. (pre-clinical) • 60% more bone after two weeks • Significantly higher removal-torque values Multicenter study (clinical) • Aggressive protocol • 98% survival rate (industry average: 95%) Osstell study (clinical) • Eliminates the dip • Significantly higher implant stability b
Slide 17: An innovative non-invasive solution for comparing implant stability
An innovative non-invasive solution for comparing implant stability Osstell™ device used in RCT study to determine comparative osseointegration by measuring resonance frequency 17
Slide 18: Osstell clinical study
Osstell™ clinical study* Design: Prospective randomized controlled clinical trial in 29 patients, each with 2 implants in positions FDI 4-7 Aim: Comparison of implant stability between SLActive and SLA at weekly intervals up to 6 weeks after placement * Investigators: D. Cochran, University of Texas
Slide 19: Osstell clinical study - outcome
Osstell™ clinical study - outcome Osseointegration with SLActive was twice as fast (2 weeks vs. 4 weeks) compared with SLA 19
Slide 20: Osstell clinical study - conclusions
Osstell™ clinical study - conclusions* • Highly significant difference in stability patterns between SLActive and SLA during critical early treatment period (2-4 weeks after placement) • Osseous healing occurs much faster around hydrophilic SLActive implant surface than conventional hydrophobic surf
Slide 21: Multicenter clinical study
Multicenter clinical study Scope • 19 centers worldwide • Aggressive protocol: focus on immediate and early loading • Patients randomized to receive provisional restoration immediately or early, at 4 weeks • 288 patients randomized • 363 implants placed Findings update • Promising survival rate of 9
Slide 22: Indication segments
oe ae _ Indication segments sinely dithe mace toe 74% i Indication segment of SLActive: 35% of the market 22
Slide 23: Clinical benefits
Clinical benefits • Reduced healing time from 6-8 to 3-4 weeks • Higher security significantly more bone after 2 weeks (on entire surface, not just thread contours) • New treatment options early loading* and critical indications *FDA 510(k) clearance for immediate loading and restoration 23
Slide 24: New product launches
New product launches Sandro Matter Executive Vice President, Products 24
Slide 25: Innovative production technology
Innovative production technology Card box Blister Implant vial 25
Slide 26: Launch program
Launch program 18.6.05 20.9.05 10.3.06 Scientific presentation Launch Launch ITI WS EU/Asia North America EAO Munich AO Seattle Launch @ EAO Munich 26
Slide 27: A highly valuable solution
A highly valuable solution SLActive is priced 30% above SLA, reflecting: • its clear, scientifically proven clinical benefits • its new convenient packaging/handling • its complex manufacturing process • Straumann’s high level of investment • the avoidance of implant failure cost (approx. € 2700) 27
Slide 28: Naturally attractive
_ Naturally attractive” “ers ale _* For more informeition, visit our website at: a. ¢@ www.straumann.com/ slactive t..' 6 @ . 6 .% S LAc tive i Naturally attractive. ( GC ga 28
Slide 29: Corporate Forum – SLActive: Activating Biology
Corporate Forum – 2 p.m. today SLActive: Activating Biology 29
Slide 30: Other new solutions for critical/challenging indications
Other new solutions for critical/challenging indications 30
Slide 31: Our strategy for oral tissue regeneration
Our strategy for oral tissue regeneration Tooth preservation Tooth replacement Bone Block Fixation (BBF) BBF Bone Ceramic Ceramic Membrane & Bone Emdogain® Dental Implants Solution for wide intrabony defects Solution for peri-implant defects 31
Slide 32: Straumann Bone Ceramic - market acceptance test results
Straumann Bone Ceramic - market acceptance test results Currently-used bone substitutes* Xenogenic 32% • >600 practitioners in 13 European countries and the US approached Unspecified 49% • High response rate (65%) • >6000 units of Straumann Bone Ceramic distributed Synthetic Allogenic 16% • >1500 qu
Slide 33: Straumann Bone Ceramic
Straumann Bone Ceramic • Fully synthetic bone substitute with optimized morphology leading the way to new vital bone • Bi-phasic calcium phosphate: HA protects from excessive resorption TCP initiates mineralization • Excellent wetting and handling properties • Specially designed convenient container
Slide 34: Straumann Bone Ceramic launch plan
Straumann Bone Ceramic launch plan • US: now available • Europe & Asia: 2006 34
Slide 35: Straumann CARES Ceramic
Straumann CARES Ceramic • Esthetic perfection • Straumann on Straumann • Guaranteed reliability erlin B GI in theD n, at soo ming C o 35
Slide 36: Questions & Answers
Z straumann Questions & Answers 36
Slide 37: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements”, which can be identified by use of terminology such as “implications”, “expect”, “provide”, “option”, “increasing”, “trend”, “plan”, “launch”, “heal”, or similar wording. Such forward-looking statements reflect the current vi